Effect of Cytomegalovirus Viremia on Subclinical Rejection or Interstitial Fibrosis and Tubular Atrophy in Protocol Biopsy at 3 Months in Renal Allograft Recipients Managed by Preemptive Therapy or Antiviral Prophylaxis
- 15 February 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 87 (3) , 436-444
- https://doi.org/10.1097/tp.0b013e318192ded5
Abstract
Background. Cytomegalovirus (CMV) is a risk factor for acute renal allograft rejection. The aim of this study was to determine the impact of CMV viremia on subclinical rejection (SCR) and interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsy at 3 months after transplantation. Methods. A total of 118 consecutive renal transplant recipients at risk for CMV (donor and recipient CMV seropositive) were included and followed up prospectively. Protocol biopsies with sufficient tissue were obtained in 102 patients. CMV activity was monitored using real-time polymerase chain reaction in whole blood. Three-month prophylaxis with valacyclovir or ganciclovir was given in 60 patients, whereas the remaining 42 patients were managed by preemptive therapy. Multivariate logistic stepwise regression analysis was used to estimate the effect of CMV viremia and other covariates on SCR and IF/TA. Results. CMV viremia occurred in 41% of the patients with a median peak viral load of 1300 copies/mL. The incidence of SCR and IF/TA was 29% and 28%, respectively. CMV viremia was not a risk factor for SCR (OR=0.77, P=0.551); however, viremia of more than or equal to 2000 copies/mL increased the risk of IF/TA (OR=3.83, P=0.023). Biopsy-proven acute rejection (OR=3.34, P=0.009) and sirolimus-based immunosuppression (OR=6.13, P=0.008) were independent predictors of SCR. Delayed-graft function (OR=6.02, P=0.001) and donor age (OR=1.53 per 10-year increase, P=0.009) were associated with IF/TA. Conclusions. CMV viremia is not an independent risk factor for SCR. CMV viremia with viral load of more than or equal to 2000 copies/mL is associated with increased risk of IF/TA in protocol biopsy at 3 months after transplantation.Keywords
This publication has 35 references indexed in Scilit:
- Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney TransplantationClinical Infectious Diseases, 2008
- Cytomegalovirus-associated allograft rejection in heart transplant patientsCurrent Opinion in Infectious Diseases, 2007
- Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challengesCurrent Opinion in Infectious Diseases, 2007
- Banff ’05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (’CAN’)American Journal of Transplantation, 2007
- Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survivalTransplant International, 2006
- Cytomegalovirus infection in solid organ transplant recipients: New challenges and their implications for preventive strategiesJournal of Clinical Virology, 2006
- Reproducibility of the Banff classification in subclinical kidney transplant rejectionClinical Transplantation, 2005
- The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients1Transplantation, 2003
- The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation1, 2Transplantation, 2002
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999